Objective-To compare the efficacy and tolerability of hydrochlorothiazide, sustained release verapamil, and their combination in patients with mild to moderate hypertension.
open trial of combined treatment for patients not achieving the target diastolic blood pressure (<90 mm Hg) during treatment with a single drug.
Setting-Outpatient departments in 10 clinics and 10 private practices of general practitioners or internists.
Patients-369 Hypertensive patients with a diastolic blood pressure of 95-120 mm Hg during a placebo run in period of two weeks.
Interventions-Initial treatment consisted of 12*5 mg hydrochlorothiazide (n= 187) or 120 mg sustained release verapamil (n= 182) once daily (regimen I). If the target diastolic blood pressure of <90 mm Hg was not achieved within four weeks doses were increased to 25 mg hydrochlorothiazide or 240 mg verapamil once (regimen II) and twice daily (regimen III). Patients not achieving target blood pressure were given the combination of hydrochlorothiazide and verapamil-that is, 25 and 240 mg once (regimen IV) and twice daily (regimen V).
Main outcome measure-Blood pressure determined with a device permitting automatic repeated measurements with printouts. Results-After eight weeks of treatment with a single drug 76 out of 178 (43%) and 101 out of 175 (58%) patients achieved the target blood pressure with hydrochlorothiazide and verapamil, respectively. During follow up until 48 weeks patients treated with verapamil reached the target blood pressure more often and at lower doses and were less likely to switch to combination treatment than patients randomised to hydrochlorothiazide treatment. Adding verapamil to hydrochlorothiazide was more effective than the addition of hydrochlorothiazide to verapamil. At the end of the study 42 out of 169 (25%) and 73 out of 163 (45%) patients initially randomised to hydrochlorothiazide and verapamil, respectively, were at target blood pressure without combination treatment. After adding verapamil to hydrochlorothiazide or hydrochlorothiazide to verapamil an additional 58 (34%) and 29 (18%) patients reached the target blood pressure, respectively. Altogether 92 out of 332 (28%) patients failed to achieve target blood pressure with regimen V. There were four, 10, seven, and seven withdrawals due to possible adverse effects to treatment with hydrochlorothiazide, verapamil, combining verapamil with hydrochlorothiazide, and combining hydrochlorothiazide with verapamil, respectively.
Conclusions-In doses currently used in antihypertensive treatment verapamil was more effective than hydrochlorothiazide as a single agent and in combination in mild to moderate hypertension, whereas withdrawal rates caused by side effects possibly related to treatment were similar.
Introduction
Over the past decade several new drugs have been introduced to treat hypertension, thus providing alternative options for treatment. Many authorities and expert organisations world wide, however, still recommend thiazide diuretics and i blockers as first line drugs for the treatment of hypertension.' 2 As single agents or with the addition of other agents, the two kinds of drugs have been compared as initial treatment in three long term controlled trials and could not be shown to affect differentially overall cardiovascular morbidity and mortality.35 There has been concern, however, about the potential disadvantages of both these groups of antihypertensive agents, such as subjective side effects and electrolyte or metabolic disturbances.
In the past few years calcium antagonists have been recommended for the treatment of hypertension.67 The selection of a new antihypertensive agent or a modification of the commonly used stepped care approach to antihypertensive treatment, however, presupposes that the new drug has been proved to be superior, or at least equivalent to, the standard treatment. Thus there is a need for long term studies of sufficient numbers of patients to compare the antihypertensive efficacy, tolerability, and adverse drug reactions of the new therapeutic regimen with the standard treatment. Therefore, in a double blind controlled study over one year we evaluated the thiazide diuretic hydrochlorothiazide and the calcium antagonist verapamil within the scope of a comparative therapeutic trial in patients with mild to moderate hypertension.
Patients and methods
The design was a multicentre, randomised, double blind, controlled clinical trial with a single blind placebo baseline period of two weeks. This was preceded by an additional wash out period of two weeks for patients who had been previously treated with antihypertensive drugs. The study population comprised male and female outpatients who had (n=239) or Results
COMPARABILITY OF GROUPS
The 369 patients who entered the trial were randomised to hydrochlorothiazide (n= 187) and verapamil (n= 182). On entry into the double blind part of the study the two groups were well balanced with regard to systolic and diastolic blood pressures, heart rate, sex, BMJ VOLUME 299 7 OCTOBER 1989weight, and previous treatment (table I) . Patients randomised to verapamil treatment were 3 3 years older than those given hydrochlorothiazide.
WITHDRAWALS
During the study 37 patients (15 given hydrochlorothiazide, 10 given verapamil, and 12 given both) withdrew for reasons considered to be unrelated to treatment, mainly because of patient non-compliance or protocol violation by family doctors not participating in the study, inability to keep the regular appointments, new serious diseases, and emergence of a new exclusion criterion (table II) .
In addition, 38 patients discontinued active treatment because of adverse effects (n=28) or an increase of diastolic blood pressure above 120 mm Hg (n= 10). Furthermore, 79 patients were withdrawn from the study because they did not achieve the target blood pressure of <90 mm Hg diastolic after being at least two weeks on the highest combination dose (regimen V). verapamil was effective in more patients than hydrochlorothiazide. The cumulative rates of response for verapamil and hydrochlorothiazide after 24 weeks were respectively 6% and 1% (regimen I), 29% and 13% (regimens I and II), and 47%/o and 27% (regimens I, II, and III). The corresponding rates after 48 weeks were 3% and 1%, 25% and 14%, and 45% and 25%.
According to subgroup analyses, similar results were obtained in male and female patients as well as in patients with and without previous antihypertensive treatment and in patients from clinical outpatient departments and private practices. The target diastolic blood pressure was achieved more often with verapamil than with hydrochlorothiazide. With both drugs the rates of response increased with age. At all ages, however, treatment with verapamil alone reduced diastolic blood pressure more often below 90 mm Hg than that with hydrochlorothiazide (table IV) . A similar observation proved true for subgroups with lower and higher than median diastolic blood pressure at entry (103 mm Hg): in both groups patients achieved target blood pressure more often during treatment with verapamil alone than with hydrochlorothiazide alone. After both hydrochlorothiazide and verapamil, however, patients with lower initial blood pressure had higher rates of response than those with higher initial blood pressure (table IV) .
If diastolic blood pressure was not reduced below 90 mm Hg with treatment with a single drug, combination treatment was started. More (table I) . Increasing dose regimens were given to achieve the target blood pressure, and patients who did not reach the target having received the highest dose were withdrawn from the study. Therefore blood pressure is given for all patients remaining in the study rather than for each treatment group, which would be misleading. Altogether, blood pressure was reduced from 152-4 (15-7)/104-3 (6 2) to 132-1 (15-4)/86-4 (7-1) mm Hg (table V) . At all time points during-the study, however, more patients remained taking verapamil alone than hydrochlorothiazide alone.
ADVERSE EFFECTS
The number of withdrawals because of major adverse effects and the complaints leading to withdrawal are listed in 93-4)9-2) 91-3 /9-1 88-2 /7-6) 871 (7-1) 86-4(7 1) 
Patients not achieving the target blood pressure with the highest dose regimen (V) were withdrawn from the study. Therefore the design of the protocol implies that the two drugs tested must be compared by the number and the rate of patients achieving the target blood pressure during the double blind period of the study rather than by the reduction in blood pressure. Secondly, the combination of the two drugs in the open part of the study answers the question whether the efficacy of the combination is dependent on the type of drug used to start treatment. Thirdly, in contrast with many other multicentre studies the present trial took advantage of an automatic blood pressure device with printouts ensuring standardisation and verification of the measurements.
In our patients with diastolic blood pressures of 95 to 120 mm Hg at entry more patients achieved the target blood pressure with verapamil alone than with hydrochlorothiazide alone. Thus with verapamil 58%, 47%, and 45% of patients showed a reduction in diastolic pressure to <90 mm Hg after eight, 24, and 48 weeks of active treatment compared with 430/o, 27%, and 25% with hydrochlorothiazide. Verapamil proved to be significantly more effective than hydrochlorothiazide with all regimens. Therefore more patients remained taking verapamil alone (n=75) than hydrochlorothiazide alone (n=44) until the end of the study. With respect to the response rate-that is, percentage of patients achieving the target diastolic blood pressure of <90 mm Hg-verapamil was superior to hydrochlorothiazide also in several subgroups defined afterwards by sex, pretreatment state, care in clinics or practices, and age. These results corroborate our main findings.
The percentage of responders in our study seems rather low. Higher rates of response have, however, been reported, mostly from uncontrolled trials. In our study an adequate placebo period preceded the start of drug treatment, the mean blood pressure at entry was rather high, and a low target blood pressure was chosen. Thus a patient was defined as a non-responder if he or she failed to achieve a diastolic blood pressure of <90 mm Hg at a single visit. When the doses used and the blood pressures at entry are taken into account the efficacy of hydrochlorothiazide in lowering blood pressure in our study compares adequately with results from other controlled trials.''O2 Verapamil has been shown to be superior to hydrochlorothiazide in the three regimens used. It pressure with a daily dose of 12 5 mg hydrochlorothiazide after 24 and 48 weeks of treatment, respectively. On the other hand, the same strategy led us to choose a daily dose of 120 mg verapamil, for which an antihypertensive effect had not been shown at the time we started our study. According to our protocol, the blood pressure was measured at the end of the dosing interval and before the administration of the next dose. Therefore another possible, but rather unlikely, explanation for the higher response rates with verapamil compared with hydrochlorothiazide is that the duration of action of sustained release verapamil is longer than that of hydrochlorothiazide.
Combining the two drugs tested in patients who did not achieve the target blood pressure with a single drug resulted in higher rates of response when verapamil was added to hydrochlorothiazide than when hydrochlorothiazide was added to verapamil. Therefore the total response rate using single drug treatment and combining the two drugs was almost identical (74%YO and 73% at 24 weeks and 59% and 63% at 48 weeks; table III) and independent of whether treatment was started with the diuretic or the calcium antagonist. On the other hand, this implies that a considerable proportion of patients will achieve the target blood pressure with verapamil alone who would need combination treatment if they were first treated with hydrochlorothiazide.
Each instance of a patient refusing to take the drug or to continue to attend the scheduled visits because of side effects was coded as a treatment related cause. The number of adverse effects leading to withdrawal from randomised treatment was low for both drugs. There were more withdrawals possibly related to adverse effects during treatment with verapamil alone than with hydrochlorothiazide alone (10 v four). Because Factors that may explain these differences are not easily identified, though selective migration, poorer diet, higher levels of smoking, and the more unfavourable climate may all contribute. We present evidence on the association between mortality and a measure of deprivation in Scotland and England and Wales that suggests that much excess mortality could be associated with the more adverse socioeconomic circumstances experienced in Scotland, deprivation presenting a picture of differences in the populations that is not present in the distribution of social class.
Method
We calculated deprivation scores for the postcode sectors in Scotland and wards in England and Wales from the 1981 census and mortality for 1980-2 by age, sex, and category of deprivation for Scotland, which provided the basis for calculating expected deaths in England and Wales. Compared with the observed deaths these provided standardised mortality ratios that took into account differences in the material circumstances of the two populations.
The deprivation measure was based on four census variables: overcrowding, unemployment among men, low social class, and not having a car. These were combined into a single score for each postcode sector in Scotland (n=about 1000) by means of thie Z score technique. Th-e value of each component variable for a sector was standardised to have a mean of zero and standard deviation of 1 by subtracting the mean value for the population (or Scotland) and then dividing by its respective population standard deviation. The four standardised component variables were then added together into one score that had a population mean of zero and standard deviation of 1. The resulting distribution was split on an arbitrary basis into seven categories ranging from very affluent to very deprived. These categories were designed to maintain the discrimination in the population, with most being allocated to the three middle categories and smaller
